Search Results - "Rambarat, Paula K."

Mechanism of β2AR regulation by an intracellular positive allosteric modulator by Liu, Xiangyu, Masoudi, Ali, Kahsai, Alem W, Li-Yin, Huang, Pani Biswaranjan, Staus, Dean P, Shim, Paul J, Hirata Kunio, Simhal, Rishabh K, Schwalb, Allison M, Rambarat, Paula K, Ahn Seungkirl, Lefkowitz, Robert J, Kobilka, Brian

“…Positive reinforcement in a GPCRMany drug discovery efforts focus on G protein–coupled receptors (GPCRs), a class of receptors that regulate many physiological…”
Get full text

Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque by Drobni, Zsofia D., Alvi, Raza M., Taron, Jana, Zafar, Amna, Murphy, Sean P., Rambarat, Paula K., Mosarla, Rayma C., Lee, Charlotte, Zlotoff, Daniel A., Raghu, Vineet K., Hartmann, Sarah E., Gilman, Hannah K., Gong, Jingyi, Zubiri, Leyre, Sullivan, Ryan J., Reynolds, Kerry L., Mayrhofer, Thomas, Zhang, Lili, Hoffmann, Udo, Neilan, Tomas G

“…BACKGROUND:Immune checkpoint inhibitors (ICI) treat an expanding range of cancers. Consistent basic data suggest that these same checkpoints are critical…”
Get full text

Unique Positive Cooperativity Between the β-Arrestin-Biased β-Blocker Carvedilol and a Small Molecule Positive Allosteric Modulator of the β2-Adrenergic Receptor by Pani, Biswaranjan, Ahn, Seungkirl, Rambarat, Paula K, Vege, Shashank, Kahsai, Alem W, Liu, Andrew, Valan, Bruno N, Staus, Dean P, Costa, Tommaso, Lefkowitz, Robert J

“…Among β -blockers that are clinically prescribed for heart failure, carvedilol is a first-choice agent with unique pharmacological properties. Carvedilol is…”
Get full text

Coronary Computed Tomographic Angiography With Fractional Flow Reserve in Patients With Type 2 Myocardial Infarction by McCarthy, Cian P., Murphy, Sean P., Amponsah, Daniel K., Rambarat, Paula K., Lin, Claire, Liu, Yuxi, Mohebi, Reza, Levin, Allison, Raghavan, Avanthi, Miksenas, Hannah, Rogers, Campbell, Wasfy, Jason H., Blankstein, Ron, Ghoshhajra, Brian, Hedgire, Sandeep, Januzzi, James L.

“…BACKGROUNDType 2 myocardial infarction (T2MI) related to a supply/demand imbalance of coronary blood flow is common and associated with poor prognosis…”
Get full text

Unique Positive Cooperativity Between the β -Arrestin-Biased β -Blocker Carvedilol and a Small Molecule Positive Allosteric Modulator of the β 2-Adrenergic Receptor by Pani, Biswaranjan, Ahn, Seungkirl, Rambarat, Paula K, Vege, Shashank, Kahsai, Alem W, Liu, Andrew, Valan, Bruno N, Staus, Dean P, Costa, Tommaso, Lefkowitz, Robert J

“…Among -blockers that are clinically prescribed for heart failure, carvedilol is a first-choice agent with unique pharmacological properties. Carvedilol is…”
Get full text

Obesity Modifies Clinical Outcomes of Right Ventricular Dysfunction by Ma, Janet I, Zern, Emily K, Parekh, Juhi K, Owunna, Ndidi, Jiang, Nona, Wang, Dongyu, Rambarat, Paula K, Pomerantsev, Eugene, Picard, Michael H, Ho, Jennifer E

“…Right ventricular (RV) dysfunction is associated with increased mortality across a spectrum of cardiovascular diseases. The role of obesity in RV dysfunction…”
Get full text

Mechanism of β 2 AR regulation by an intracellular positive allosteric modulator by Liu, Xiangyu, Masoudi, Ali, Kahsai, Alem W, Huang, Li-Yin, Pani, Biswaranjan, Staus, Dean P, Shim, Paul J, Hirata, Kunio, Simhal, Rishabh K, Schwalb, Allison M, Rambarat, Paula K, Ahn, Seungkirl, Lefkowitz, Robert J, Kobilka, Brian

“…Drugs targeting the orthosteric, primary binding site of G protein-coupled receptors are the most common therapeutics. Allosteric binding sites, elsewhere on…”
Get full text

Sex Differences in Coronary Artery Disease Characteristics Among Patients With Type 2 Myocardial Infarction by Lin, Claire, McCarthy, Cian P., Mohebi, Reza, Liu, Yuxi, Blankstein, Ron, Murphy, Sean P., Miksenas, Hannah, Rogers, Campbell, Amponsah, Daniel K., Rambarat, Paula K., Raghavan, Avanthi, Levin, Allison, Ghoshhajra, Brian, Wasfy, Jason H., Hedgire, Sandeep, Januzzi, James L.

“…Type 2 myocardial infarction (MI) results from coronary supply and demand imbalance and has a poor prognosis. It is crucial to identify potential sex-based…”
Get full text

Pre-Existing Autoimmune Disease Increases the Risk of Cardiovascular and Noncardiovascular Events After Immunotherapy by Lee, Charlotte, Drobni, Zsofia D., Zafar, Amna, Gongora, Carlos A., Zlotoff, Daniel A., Alvi, Raza M., Taron, Jana, Rambarat, Paula K., Schoenfeld, Sara, Mosarla, Ramya C., Raghu, Vineet K., Hartmann, Sarah E., Gilman, Hannah K., Murphy, Sean P., Sullivan, Ryan J., Faje, Alexander, Hoffmann, Udo, Zhang, Lili, Mayrhofer, Thomas, Reynolds, Kerry L., Neilan, Tomas G.

“…The use of immune checkpoint inhibitors (ICI) is associated with cardiovascular (CV) events, and patients with pre-existing autoimmune disease are at increased…”
Get full text

Small-Molecule Positive Allosteric Modulators of the β 2 -Adrenoceptor Isolated from DNA-Encoded Libraries by Ahn, Seungkirl, Pani, Biswaranjan, Kahsai, Alem W, Olsen, Eva K, Husemoen, Gitte, Vestergaard, Mikkel, Jin, Lei, Zhao, Shuai, Wingler, Laura M, Rambarat, Paula K, Simhal, Rishabh K, Xu, Thomas T, Sun, Lillian D, Shim, Paul J, Staus, Dean P, Huang, Li-Yin, Franch, Thomas, Chen, Xin, Lefkowitz, Robert J

“…Conventional drug discovery efforts at the -adrenoceptor ( AR) have led to the development of ligands that bind almost exclusively to the receptor's…”
Get more information

Association between incidental statin use and skeletal myopathies in patients treated with immune checkpoint inhibitors by Drobni, Zsofia D, Murphy, Sean P, Alvi, Raza M, Lee, Charlotte, Gong, Jingyi, Mosarla, Ramya C, Rambarat, Paula K, Hartmann, Sarah B, Gilman, Hannah K, Zubiri, Leyre, Raghu, Vineet K, Sullivan, Ryan J, Zafar, Amna, Zlotoff, Daniel A, Sise, Meghan E, Guidon, Amanda C, Reynolds, Kerry L, Dougan, Michael, Neilan, Tomas G

“…Skeletal myopathies are highly morbid, and in rare cases even fatal, immune-related adverse events (irAE) associated with immune checkpoint inhibitors (ICI)…”
Get full text

CARDIOVASCULAR AND CEREBROVASCULAR EVENTS AMONG PATIENTS RECEIVING IMMUNE CHECKPOINT INHIBITORS by Alvi, Raza, Drobni, Zsofia, Zafar, Amna, Zhang, Lili, Taron, Jana, Zlotoff, Daniel, Rokicki, Adam, Raghu, Vineet K., Mosarla, Rayma C., Murphy, Sean, Rambarat, Paula K., Sullivan, Ryan, Reynolds, Kerry L., Hoffmann, Udo, Neilan, Tomas G.

Get full text

Abstract 14600: Pre-existing Autoimmune Disease and the Risk for Cardiovascular and Non-cardiovascular Immune Mediated Adverse Events With Immune Checkpoint Inhibitors by Lee, Charlotte, Drobni, Zsofia D, Zafar, Amna, Alvi, Raza M, Murphy, Sean P, Mosarla, Ramya C, Rambarat, Paula K, Hartmann, Sarah B, Gilman, Hannah K, Zubiri, Leyre, Raghu, Vineet K, Sullivan, Ryan J, Zlotoff, Daniel A, Faje, Alexander, Reynolds, Kerry L, Neilan, Tomas G

“…IntroductionThe use of immune checkpoint inhibitors (ICIs) is associated with an increase in cardiovascular events. The mechanism is likely related to immune…”
Get full text